Ipamorelin's marketing slogan — "the gentle giant" — tells you exactly how it is positioned: growth hormone stimulation with none of the messy cortisol spikes that come with less selective peptides like GHRP-2 or GHRP-6. This selectivity is real. The fat loss that follows from it is where the claim chain starts to break down.

The Selectivity Claim Is Real. The Fat Loss Derivation Is Not.

Ipamorelin (also written as Ipamorline) is a synthetic growth hormone secretagogue that was first characterized in the late 1990s. Its key pharmacological distinction is that it is a relatively selective GHRP receptor agonist — primarily GHRP-2 (ghrelin receptor) — with a more favorable ratio of GH stimulation to ACTH/cortisol stimulation compared to non-selective GHRPs. This is real and documented in animal studies.

The problem is the jump from "Ipamorelin stimulates GH release selectively" to "Ipamorelin produces meaningful fat loss." Growth hormone does affect lipolysis — the breakdown of stored fat — and GH-deficient individuals do accumulate excess adipose tissue. But the relationship between pharmacologically elevating GH in adults with normal GH levels and meaningful body composition changes is not straightforward.

The "zero cortisol spike" and fat loss claims got a 4/10 — not because cortisol is irrelevant or because GH stimulation is fake, but because the direct translation from GH stimulation to clinically meaningful fat loss in non-GH-deficient adults is not supported by controlled human data.

What the Human Studies Show

Ipamorelin has been studied in humans primarily for its effect on GH secretion, not body composition. The most relevant study is a 2004 trial in healthy young women where Ipamorelin increased GH and GH-dependent markers, but body composition endpoints were not reported. There are no large, randomized, placebo-controlled trials of Ipamorelin for fat loss in humans.

The animal data is where the fat loss story lives. Early rodent studies showed Ipamorelin increased GH and reduced body fat in obese mice. This is the source of the fat loss claim in humans. The problem: rodent obesity models and adult human body composition are fundamentally different contexts. What works in a mouse on a high-fat diet does not trivially transfer to a human doing a "cut."

The Cortisol Selectivity Argument (And Its Limits)

Non-selective GHRPs (GHRP-2, GHRP-6) stimulate GH but also stimulate ACTH, which increases cortisol. Cortisol is catabolic — it breaks down muscle and promotes fat deposition in the long term — so for body composition purposes, you want GH stimulation without cortisol stimulation. Ipamorelin's selectivity for GHRP-2 over other pathways is the theoretical basis for the "clean" framing.

This is biochemically plausible. But it assumes the cortisol problem is the limiting factor in GH-mediated fat loss, which is a bigger assumption than the peptide clinics present. If the real constraint on GH-mediated fat loss is baseline insulin sensitivity, dietary adherence, or training stimulus — factors the cortisol difference doesn't affect — then paying premium prices for Ipamorelin's selectivity advantage over GHRP-2 is a very expensive optimization for a marginal difference in outcome.

The Peptide Stacking Problem

Ipamorelin almost never appears alone in practice. It is almost always stacked with CJC-1295 (or the DAC version) as part of a broader "GHRH + GHRP" protocol — the combination is theoretically synergistic (CJC-1295 extends the GH pulse, Ipamorelin amplifies it). This stacking is presented in clinic protocols as standard practice.

But when Ipamorelin is studied in a stack, the outcomes attributed to Ipamorelin specifically cannot be disentangled from the CJC-1295 effects, or from the diet and training changes that patients are simultaneously implementing. Any fat loss observed in patients on Ipamorelin+CJC-1295 stacks cannot be attributed to Ipamorelin alone. This is a fundamental confound in nearly all real-world peptide protocol data.

What Would Actually Validate the Fat Loss Claim

A properly designed trial would take adults with above-average body fat percentages, randomize them to Ipamorelin vs. placebo, keep diet and exercise controlled across both groups, and measure body composition (via DEXA, not scale weight) at baseline and at 12-16 weeks. That trial does not exist. We have: animal studies showing fat loss, pharmacokinetic data showing GH stimulation in humans, and uncontrolled anecdotal reports from peptide clinic patients who are simultaneously changing their diet and training.

The fat loss claim requires a controlled human trial. Absent that, we're reasoning from mechanism to effect without the intervening evidence.

Bottom Line

Ipamorelin's GH-releasing effect is real and its selectivity advantage over non-selective GHRPs is biochemically defensible. The fat loss extrapolation — which is the main reason most people are sold on it — requires controlled human trial data that does not exist. The people reporting fat loss on Ipamorelin protocols are almost always simultaneously doing the dietary and training work that actually drives body composition change. Ipamorelin's contribution to that outcome is unquantified and possibly marginal.

If you're going to run a GH secretagogue protocol, Ipamorelin's selectivity profile is more defensible than GHRP-2 or GHRP-6 on theoretical grounds. But the selection of which secretagogue to use is a rounding error compared to the selection of whether to implement the diet and training changes that actually move body composition. Don't confuse the expensive optimization for the foundational work.